• Home
• News
• About Us
• Contact

Search

Tag Cloud

anthrax Strategic National Stockpile Training exercise Bioterror Biomagnetics National Research Council Homeland Security Biodefense lab Army Medical Research Institute antibiotics Emergency preparedness research Bioweapons NIAID smallpox Detection technology CDC TSA Defense Dept IAEM FEMA immunization Ebola Ricin Hendra Plague treaty West Nile Camouflage Paint Marburg antidote weapons destruction Sarin VHF viruses chemical disposal dna technology prevention Robotics Technology research grants tularemia weapons control foot and mouth disease decontamination E. coli Iraq missile defense Bio-Rescue Dengue fever Botulinum toxin antiviral molecular diagnostics Infectious disease

Subscribe to our newsletter

RSS Feed

NIAID awards Northrop Grumman for bioinformatics resource centers
by Ted Purlain on November 5, 2009

RESTON, Va. — Northrop Grumman Corp. has been awarded a contract by the National Institute of Allergy and Infectious Diseases to create a resource that supports research of pathogenic viruses.

NIAID to fund development of Emergent BioSolutions' vaccine candidate
by Mary J. Lewis on November 4, 2009

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced Sept. 30 that it was awarded a cooperative agreement from the National Institute of Allergy and Infectious Diseases to further the development of one of its advanced anthrax vaccine candidates.

Pulmatrix receives grant to develop inhaled influenza therapeutics
by Rita Uplend on November 3, 2009

LEXINGTON, Mass. — Pulmatrix, a clinical stage biotechnology company, announced Nov. 2 that it has been awarded a $2.2 million grant from the National Institute of Allergy and Infectious Diseases.

Nanotherapeutics receives contract to develop smallpox drug
by Mary J. Lewis on October 29, 2009

ALACHUA, Fla. — Nanotherapeutics Inc. has been awarded a $30.9 million, five-year contract from the National Institute of Allergy and Infectious Diseases to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exp

NIAID awards $4.4 million to research potential anthrax attacks
by Mary J. Lewis on October 29, 2009

ALBUQUERQUE, N.M. — Lovelace Respiratory Research Institute was recently awarded a $4.4 million contract from the National Institutes of Allergy and Infectious Disease.